Sign In
Buy IOBT
$0.0480
+0 (+0%)
At Close: Jul 08, 2026
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
07:05am, Tuesday, 13'th Aug 2024
Phase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in
3 Penny Stocks with 190% Growth Potential According to Wall Street Analysts
03:27pm, Monday, 12'th Aug 2024
Penny stocks are a fascinating category of investment opportunities.
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
04:05pm, Thursday, 25'th Jul 2024
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® p
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
10:01am, Thursday, 04'th Jul 2024
One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That's because most retail investors prefer to research consumer information regard
IO Biotech to Present at Jefferies Global Healthcare Conference
08:30am, Thursday, 23'rd May 2024
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® pl
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
07:55am, Tuesday, 14'th May 2024
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® pl
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
04:30pm, Wednesday, 24'th Apr 2024
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
08:30am, Monday, 15'th Apr 2024
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
12:00pm, Tuesday, 09'th Apr 2024
NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
08:30am, Friday, 05'th Apr 2024
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
04:11pm, Wednesday, 06'th Mar 2024
New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-st
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
04:40pm, Tuesday, 05'th Mar 2024
Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; plann
IO Biotech to Present at 44th Annual Cowen Health Care Conference
04:05pm, Monday, 26'th Feb 2024
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® p
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
11:20am, Sunday, 18'th Feb 2024
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to
IO Biotech: A Phase 3 Company Getting No Respect
03:04am, Wednesday, 03'rd Jan 2024
IO Biotech is an immunotherapy biotech in phase 3 trials. Past failures of IDO as a target cast a pall on their potential data readouts. Nevertheless, the cheap stock price and upcoming catalysts make
